back to all news

OD-OS launches Pre-Planned PRP for its Navilas Laser System

Teltow, Germany – June 27, 2017 – OD-OS, the global leader in the development and commercialization of navigated retinal laser systems, today announced the market release of its unique pre-planned PRP capability for Navilas 577s.

Pre-planned PRP allows the physician to lay out the treatment strategy for the peripheral retina before commencing treatment. Besides rapid and uniform coverage for PRP this allows specifically targeted treatments based on imported third party images (such as ultra-wide-field FA) as well as easy laser retinopexy treatments. This complements the focal planning capability that has been the signature feature for Navilas since its inception.

A video highlighting these treatment options can be found on the OD-OS website: https://www.od-os.com/navilas-rapid-prp/

 “We are glad to extend retinal laser pre-planning to peripheral treatments now,” said Monika Ranta, International Sales Director at OD-OS, “PRP once used to be a tedious procedure for physicians and patients alike. Then we introduced the pattern laser for faster treatments and now we are taking peripheral retina treatments to the next level, by giving trainees easy access to learn the technique and allowing experts to perform sophisticated selectively-targeted treatments previously unseen.”

David Brown, MD (Retina Consultants of Houston, TX) was the first U.S. physician to treat patients with the new Navilas 577s before FDA clearance during his visit to Berlin, Germany, "I am very impressed with the new Navilas 577s PRP. It feels ergonomic and straightforward - the system literally lets me paint the peripheral retina with uniform spots in a very short amount of time. It was very well tolerated by the patients, with only topical anesthesia. Navilas now has an industry leading PRP tool to complement its unrivalled and already well-known focal laser capability."

Navilas 577s enables physicians to digitally pre-plan the entire laser therapy on fundus images as well as external diagnostic images and precisely execute this therapy plan under computer guidance. Unlike any other retina laser, Navilas offers focal treatments without a contact lens and infrared illumination for unsurpassed patient comfort.  A large field of view and assisted pattern positioning greatly improve speed in panretinal and focal treatments.

Indications for use: Navilas® Laser System 577s and the Navilas Laser System 577+ are retinal photocoagulators integrated with a digital fundus camera. They are indicated for use in
•    Retinal Photocoagulation for the treatment of Clinically Significant Diabetic Macular Edema (Focal or Grid Laser), Proliferative Diabetic Retinopathy (Panretinal Photocoagulation), Sub-retinal (Choroidal) Neovascularization (Focal Laser), Central and Branch Retinal Vein Occlusion (Scatter Laser Photocoagulation, Focal or Grid Laser), Lattice Degeneration, Retinal Tears and Detachments (Laser Retinopexy).
•    Imaging (capture, display, storage and manipulation) of the retina of the eye, including color and infrared imaging; and for aiding in the diagnosis and treatment of ocular pathology in the posterior segment of the eye.

OD-OS is the first and only company to develop and commercialize Navigated Laser treatments in Ophthalmology.

About OD-OS:    
OD-OS, Inc., a privately-held medical device company founded in 2008 with offices in Teltow, Germany and Irvine, Calif., is dedicated to the development and commercialization of advanced navigated imaging and laser treatment technology used to facilitate the advanced treatment of retinal eye diseases, many of which may lead to permanent blindness. Visit www.od-os.com for more details.

For further information, please contact:

Dr. Erik Blazek, Director Marketing | erik.blazek@od-os.com, +49 (172) 324 90 31
OD-OS GmbH | Warthestr. 21 | 14513 Teltow | Germany | Phone.: +49 (3328) 312 82 100
info@od-os.com | www.od-os.com 

back to all news